Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
167.2 EUR | -0.89% | +7.52% | +16.03% |
16.05. | DZ Bank hebt fairen Wert für Merck KGaA auf 201 Euro - 'Kaufen' | DP |
16.05. | Barclays hebt Ziel für Merck KGaA auf 205 Euro - 'Overweight' | DP |
Kurzporträt
- Lösungen und Produkte für die wissenschaftliche und biotechnologische Forschung (44,2%);
- Pharmaprodukte (38,4%): verschreibungspflichtige Medikamente zur Behandlung von Diabetes, Diabetes, Krebs, Multipler Sklerose, Unfruchtbarkeit, Herz-Kreislauf-Erkrankungen, Erkrankungen des Zentralnervensystems, Entzündungskrankheiten usw.;
- Performance-Materialien für die Elektronikindustrie (17,4%): Halbleitermaterialien, Flüssigkristalle, Pigmente und Additive, organische Materialien auf Kohlenstoffbasis, usw.
Die geografische Verteilung des Umsatzes sieht aus wie folgt: Deutschland (4,8%), Europa (24%), China (12,9%), Asien / Pazifik (20,1%), USA (26,8%), Nordamerika (1,6%), Lateinamerika (6,3%), Mittlerer Osten und Afrika (3,5%).
Mitarbeiterzahl: 62 345
Umsatz nach Geschäftsbereich
EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Life Science
44,2
%
| 10 380 | 46,7 % | 9 281 | 44,2 % | -10.59% |
Healthcare
38,4
%
| 7 839 | 35,3 % | 8 053 | 38,4 % | +2.73% |
Electronics
17,4
%
| 4 013 | 18,1 % | 3 659 | 17,4 % | -8.82% |
Umsatz je Region
EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
28,2
%
| 6 302 | 28,3 % | 5 911 | 28,2 % | -6.20% |
Europe
21,0
%
| 4 524 | 20,3 % | 4 402 | 21,0 % | -2.70% |
Asia Pacific
19,9
%
| 4 479 | 20,1 % | 4 181 | 19,9 % | -6.65% |
China
11,8
%
| 2 818 | 12,7 % | 2 477 | 11,8 % | -12.10% |
Germany
6,8
%
| 1 532 | 6,9 % | 1 420 | 6,8 % | -7.31% |
Latin America
6,0
%
| 1 175 | 5,3 % | 1 267 | 6,0 % | +7.83% |
Middle East and Africa
2,5
%
| 516 | 2,3 % | 535 | 2,5 % | +3.68% |
Switzerland
2,4
%
| 592 | 2,7 % | 512 | 2,4 % | -13.51% |
North America
1,4
%
| 294 | 1,3 % | 287 | 1,4 % | -2.38% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | 62 | 13.07.20 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 01.08.14 |
Director of Finance/CFO | 53 | 26.04.19 | |
Laura Matz
CTO | Chief Tech/Sci/R&D Officer | - | 01.01.19 |
Danny Bar-Zohar
CTO | Chief Tech/Sci/R&D Officer | - | 01.11.20 |
Constantin Fest
IRC | Investor Relations Contact | - | - |
Jeff White
PRN | Corporate Officer/Principal | - | - |
Andrew Paterson
SAM | Sales & Marketing | - | - |
Corporate Officer/Principal | - | 01.09.21 | |
Hong Chow
PRN | Corporate Officer/Principal | 53 | 01.01.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | - |
Chairman | 67 | 26.04.19 | |
Gabriele Eismann
BRD | Director/Board Member | 62 | 01.01.91 |
Dietmar Oeter
BRD | Director/Board Member | 57 | 01.01.95 |
Barbara Lambert
BRD | Director/Board Member | 62 | 11.08.23 |
Renate Koehler
BRD | Director/Board Member | - | 26.04.19 |
Director/Board Member | - | 26.04.19 | |
Daniel Thelen
BRD | Director/Board Member | - | 26.04.19 |
Simon Thelen
BRD | Director/Board Member | 44 | 26.04.19 |
Birgit Biermann
BRD | Director/Board Member | 50 | 14.07.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 305 535 626 | 0 | 0 | 29,71 % |
Aktie B | 1 | 129 242 252 | 129 159 619 ( 99,94 %) | 0 |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
2 787 509 | 4,65% | 117 772 255 $ | |
PT MERCK TBK 86,65% | 388 194 920 | 86,65% | 97 405 869 $ |
VERA THERAPEUTICS, INC. 3,48% | 1 913 501 | 3,48% | 74 033 354 $ |
PRECIGEN, INC. 8,29% | 20 647 152 | 8,29% | 28 906 013 $ |
Unternehmenskontakt
Konzerngesellschaften
Name | Kategorie und Branche |
---|---|
Ridgefield Holdco SARL
| |
Merck Specialities Pvt Ltd.
Merck Specialities Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Merck KGaA, Merck Specialities Pvt Ltd. is a pharmaceutical manufacturing and Indian distribution company. The company is based in Mumbai, India and was founded in 2005. |
Pharmaceuticals: Major
|
Merck Finanz SARL
Merck Finanz SARL Medical/Nursing ServicesHealth Services Part of Merck KGaA, Merck Finanz SARL is a Luxembourger company that provides healthcare, life sciences, and electronic services. The company is based in Luxembourg, Luxembourg. |
Medical/Nursing Services
|
Merck Serono SA
Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. |
Medical Specialties
|
Merck Electronics KGaA
| |
Merck Life Science UK Ltd.
Merck Life Science UK Ltd. Chemicals: Major DiversifiedProcess Industries Founded in 1960, Merck Life Science UK Ltd. is a subsidiary of Merck KGaA. The company is based in Gillingham, UK. The British company provides advanced chemical materials for the manufacturing of LCD panels. |
Chemicals: Major Diversified
|
Merck BV
| |
Merck Life Science A/S
Merck Life Science A/S Electronic Equipment/InstrumentsElectronic Technology Part of Merck KGaA, Merck Life Science A/S is a Danish company that provides industrial instruments for measurement. The company is located in Denmark. |
Electronic Equipment/Instruments
|
Merck Santé SASU
Merck Santé SASU Pharmaceuticals: MajorHealth Technology Merck Santé SAS manufactures pharmaceutical products. The company is headquartered in Lyon, France. |
Pharmaceuticals: Major
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+16.03% | 79.03 Mrd. | |
+10.23% | 8.96 Mrd. | |
-10.76% | 5.19 Mrd. | |
+51.58% | 4.77 Mrd. | |
+12.50% | 4.26 Mrd. | |
-20.70% | 2.37 Mrd. | |
+12.83% | 2.3 Mrd. | |
-29.65% | 2.21 Mrd. | |
+19.51% | 2.17 Mrd. | |
-0.50% | 1.64 Mrd. |
- Börse
- Aktien
- 659990 Aktie
- Unternehmen Merck KGaA